GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » PS Ratio

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) PS Ratio : 0.00 (As of Jun. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Parnell Pharmaceuticals Holdings's share price is $0.0001. Parnell Pharmaceuticals Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2018 was $1.06. Hence, Parnell Pharmaceuticals Holdings's PS Ratio for today is 0.00.

The historical rank and industry rank for Parnell Pharmaceuticals Holdings's PS Ratio or its related term are showing as below:

PARNF's PS Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.17
* Ranked among companies with meaningful PS Ratio only.

Parnell Pharmaceuticals Holdings's Revenue per Sharefor the six months ended in Dec. 2018 was $1.06. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2018 was $1.06.

Back to Basics: PS Ratio


Parnell Pharmaceuticals Holdings PS Ratio Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings PS Ratio Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
PS Ratio
Get a 7-Day Free Trial 5.79 3.58 0.78 0.74 0.15

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
PS Ratio Get a 7-Day Free Trial 5.79 3.58 0.78 0.74 0.15

Competitive Comparison of Parnell Pharmaceuticals Holdings's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnell Pharmaceuticals Holdings's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's PS Ratio distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's PS Ratio falls into.



Parnell Pharmaceuticals Holdings PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Parnell Pharmaceuticals Holdings's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.0001/1.056
=0.00

Parnell Pharmaceuticals Holdings's Share Price of today is $0.0001.
For company reported annually, GuruFocus uses latest annual data as the TTM data. Parnell Pharmaceuticals Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2018 was $1.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Parnell Pharmaceuticals Holdings PS Ratio Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.